Question 1
A company receives multiple complaints regarding the text included on a recently launched product's
label. What action should the regulatory affairs professional take FIRST?
Question 2
Which of the following is MOST appropriate for the purpose of lot release of biologics?
Question 3
A global company is developing a sophisticated implantable medical device that is coated with antibiotics
and biologics to enhance its efficacy. The product is marketed in Country X. where it is regulated as a
medical device. The same product, without the antibiotics and biologics, is marketed as a medical device
in Country Y. The company is proposing to start marketing the coated device in Country Y. Which
regulatory approach should the company propose?
Question 4
A regulatory affairs professional has submitted a package for regulatory review. According to the
regulation, the regulatory authority will need to respond within 90 days of submission. If there is no
response after the deadline, what is the BEST approach?
Question 5
The API used for an approved drug product conforms to international monograph specifications and local
pharmacopeia; however, the international monograph specifications of the API will be changing soon.
Which is the most appropriate action for the regulatory affairs professional to take FIRST?